GSK plc (GSKN) Fair Value & Analysis

Healthcare · MX · Market cap 1.8T MXN

A solid business, screening 18% undervalued on our models.

What matters now

• A fairly wide model range (671.03 MXN to 1,543 MXN) leaves room in how you read the outcome.
• Our model range runs from 671.03 MXN (bear) to 1,543 MXN (bull), base 1,078 MXN. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 70/100 (solid quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.

How to read this chart

60‑month range 509.71 MXN – 1,031 MXN · fair‑value band 671.03 MXN – 1,543 MXN · the 917.00 MXN price screens below the 1,078 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

GSK plc (GSKN) currently trades at 917.00 MXN, while our model-based Fair Value estimate is 1,078 MXN, implying the stock looks roughly 17.6% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, GSK plc generated revenue of 32.8B MXN at a net margin of 17.8%. Revenue grew 1.5% year over year. It earns a return on equity of 40.9%. Net debt stands at 13.7B MXN. Fundamentals as of Jul 17, 2026

Our scenario range runs from 671.03 MXN (bear case) to 1,543 MXN (bull case); at 917.00 MXN, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 35% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at 18%, GSKN screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (48.52 MXN) versus Asset-Based (5.48 MXN). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.

Full company description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

GSK plc reported revenue of 32.7B MXN in FY2025 versus 34.1B MXN in FY2021, a compound −1.1%/yr. Reported net income was 5.7B MXN in FY2025, compounding +6.9%/yr from FY2021.

Watch GSKN: get an alert when its fair value changes →

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.